Corrigendum to “Pembrolizumab Plus Axitinib Versus Sunitinib as First-line Treatment of Advanced Renal Cell Carcinoma: 43-month Follow-up of the Phase 3 KEYNOTE-426 Study" [Eur Urol 84(5) (2023) 449-454]

Elizabeth R. Plimack; Thomas Powles; Viktor Stus; Rustem Gafanov; Dmitry Nosov; Tom Waddell; Boris Alekseev; Frédéric Pouliot; Bohuslav Melichar; Denis Soulières; Delphine Borchiellini; Raymond S. McDermott; Ihor Vynnychenko; Yen Hwa Chang; Satoshi Tamada; Michael B. Atkins; Chenxiang Li; Rodolfo Perini; L. Rhoda Molife; Jens Bedke; Brian I. Rini

doi:10.1016/j.eururo.2023.11.016

Corrigendum to “Pembrolizumab Plus Axitinib Versus Sunitinib as First-line Treatment of Advanced Renal Cell Carcinoma: 43-month Follow-up of the Phase 3 KEYNOTE-426 Study" [Eur Urol 84(5) (2023) 449-454]

Elizabeth R. Plimack, Thomas Powles, Viktor Stus, Rustem Gafanov, Dmitry Nosov, Tom Waddell, Boris Alekseev, Frédéric Pouliot, Bohuslav Melichar, Denis Soulières, Delphine Borchiellini, Raymond S. McDermott, Ihor Vynnychenko, Yen Hwa Chang, Satoshi Tamada, Michael B. Atkins, Chenxiang Li, Rodolfo Perini, L. Rhoda Molife, Jens BedkeBrian I. Rini

Research output: Contribution to journal › Comment/debate

Abstract

The authors regret the following errors to Fig. 1B and supplemental Fig. S5B. The Kaplan-Meier curve in Fig. 1B should start at Y = 100, and the 95% CI symbols on Fig. S5B did not match the correct values on the X-axis. These errors have now been corrected. The authors apologise for any inconvenience caused.[Formula

Original language	English
Pages (from-to)	e58-e59
Journal	European Urology
Volume	85
Issue number	2
DOIs	https://doi.org/10.1016/j.eururo.2023.11.016
State	Published - Feb 2024

Access to Document

10.1016/j.eururo.2023.11.016

Fingerprint

Dive into the research topics of 'Corrigendum to “Pembrolizumab Plus Axitinib Versus Sunitinib as First-line Treatment of Advanced Renal Cell Carcinoma: 43-month Follow-up of the Phase 3 KEYNOTE-426 Study" [Eur Urol 84(5) (2023) 449-454]'. Together they form a unique fingerprint.

Cite this

Plimack, E. R., Powles, T., Stus, V., Gafanov, R., Nosov, D., Waddell, T., Alekseev, B., Pouliot, F., Melichar, B., Soulières, D., Borchiellini, D., McDermott, R. S., Vynnychenko, I., Chang, Y. H., Tamada, S., Atkins, M. B., Li, C., Perini, R., Molife, L. R., ... Rini, B. I. (2024). Corrigendum to “Pembrolizumab Plus Axitinib Versus Sunitinib as First-line Treatment of Advanced Renal Cell Carcinoma: 43-month Follow-up of the Phase 3 KEYNOTE-426 Study" [Eur Urol 84(5) (2023) 449-454]. European Urology, 85(2), e58-e59. https://doi.org/10.1016/j.eururo.2023.11.016

@article{62059d4fbd834a5dbf21790ef4270f5e,

title = "Corrigendum to “Pembrolizumab Plus Axitinib Versus Sunitinib as First-line Treatment of Advanced Renal Cell Carcinoma: 43-month Follow-up of the Phase 3 KEYNOTE-426 Study{"} [Eur Urol 84(5) (2023) 449-454]",

abstract = "The authors regret the following errors to Fig. 1B and supplemental Fig. S5B. The Kaplan-Meier curve in Fig. 1B should start at Y = 100, and the 95% CI symbols on Fig. S5B did not match the correct values on the X-axis. These errors have now been corrected. The authors apologise for any inconvenience caused.[Formula",

author = "Plimack, {Elizabeth R.} and Thomas Powles and Viktor Stus and Rustem Gafanov and Dmitry Nosov and Tom Waddell and Boris Alekseev and Fr{\'e}d{\'e}ric Pouliot and Bohuslav Melichar and Denis Souli{\`e}res and Delphine Borchiellini and McDermott, {Raymond S.} and Ihor Vynnychenko and Chang, {Yen Hwa} and Satoshi Tamada and Atkins, {Michael B.} and Chenxiang Li and Rodolfo Perini and Molife, {L. Rhoda} and Jens Bedke and Rini, {Brian I.}",

note = "Publisher Copyright: {\textcopyright} 2023",

year = "2024",

month = feb,

doi = "10.1016/j.eururo.2023.11.016",

language = "English",

volume = "85",

pages = "e58--e59",

journal = "European Urology",

issn = "0302-2838",

publisher = "Elsevier B.V.",

number = "2",

}

Plimack, ER, Powles, T, Stus, V, Gafanov, R, Nosov, D, Waddell, T, Alekseev, B, Pouliot, F, Melichar, B, Soulières, D, Borchiellini, D, McDermott, RS, Vynnychenko, I, Chang, YH, Tamada, S, Atkins, MB, Li, C, Perini, R, Molife, LR, Bedke, J & Rini, BI 2024, 'Corrigendum to “Pembrolizumab Plus Axitinib Versus Sunitinib as First-line Treatment of Advanced Renal Cell Carcinoma: 43-month Follow-up of the Phase 3 KEYNOTE-426 Study" [Eur Urol 84(5) (2023) 449-454]', European Urology, vol. 85, no. 2, pp. e58-e59. https://doi.org/10.1016/j.eururo.2023.11.016

Corrigendum to “Pembrolizumab Plus Axitinib Versus Sunitinib as First-line Treatment of Advanced Renal Cell Carcinoma: 43-month Follow-up of the Phase 3 KEYNOTE-426 Study" [Eur Urol 84(5) (2023) 449-454]. / Plimack, Elizabeth R.; Powles, Thomas; Stus, Viktor et al.
In: European Urology, Vol. 85, No. 2, 02.2024, p. e58-e59.

Research output: Contribution to journal › Comment/debate

TY - JOUR

T1 - Corrigendum to “Pembrolizumab Plus Axitinib Versus Sunitinib as First-line Treatment of Advanced Renal Cell Carcinoma

T2 - 43-month Follow-up of the Phase 3 KEYNOTE-426 Study" [Eur Urol 84(5) (2023) 449-454]

AU - Plimack, Elizabeth R.

AU - Powles, Thomas

AU - Stus, Viktor

AU - Gafanov, Rustem

AU - Nosov, Dmitry

AU - Waddell, Tom

AU - Alekseev, Boris

AU - Pouliot, Frédéric

AU - Melichar, Bohuslav

AU - Soulières, Denis

AU - Borchiellini, Delphine

AU - McDermott, Raymond S.

AU - Vynnychenko, Ihor

AU - Chang, Yen Hwa

AU - Tamada, Satoshi

AU - Atkins, Michael B.

AU - Li, Chenxiang

AU - Perini, Rodolfo

AU - Molife, L. Rhoda

AU - Bedke, Jens

AU - Rini, Brian I.

PY - 2024/2

Y1 - 2024/2

N2 - The authors regret the following errors to Fig. 1B and supplemental Fig. S5B. The Kaplan-Meier curve in Fig. 1B should start at Y = 100, and the 95% CI symbols on Fig. S5B did not match the correct values on the X-axis. These errors have now been corrected. The authors apologise for any inconvenience caused.[Formula

AB - The authors regret the following errors to Fig. 1B and supplemental Fig. S5B. The Kaplan-Meier curve in Fig. 1B should start at Y = 100, and the 95% CI symbols on Fig. S5B did not match the correct values on the X-axis. These errors have now been corrected. The authors apologise for any inconvenience caused.[Formula

UR - http://www.scopus.com/inward/record.url?scp=85179484866&partnerID=8YFLogxK

U2 - 10.1016/j.eururo.2023.11.016

DO - 10.1016/j.eururo.2023.11.016

M3 - Comment/debate

C2 - 38071169

AN - SCOPUS:85179484866

SN - 0302-2838

VL - 85

SP - e58-e59

JO - European Urology

JF - European Urology

IS - 2

ER -

Corrigendum to “Pembrolizumab Plus Axitinib Versus Sunitinib as First-line Treatment of Advanced Renal Cell Carcinoma: 43-month Follow-up of the Phase 3 KEYNOTE-426 Study" [Eur Urol 84(5) (2023) 449-454]

Abstract

Access to Document

Other files and links

Fingerprint

Cite this